期刊文献+

上市后药物经济学评价方法Ⅱ:药物经济学原始研究 被引量:3

Methods for Economic Evaluation of Marketed Medicines Ⅱ: Conducting Primary Economic Evaluation
在线阅读 下载PDF
导出
摘要 当现有经济学证据的系统评价不能充分评价上市后药物的经济学情况时,需要开展原始的经济学评价研究。本文主要介绍了原始经济学评价中研究设计,成本和结果的测量,及敏感性分析的原则。总体而言,四种设计方案可用于经济学评价,不同方案各有其优缺点。结果和成本的测量方法有多种,主要根据研究要求和适用性选择不同的方法。对各种可能影响结果的因素应采用不同的分析方法进行分析。 Primary economic evaluations are needed in the case that the systematic review of existing economic evidence is not capable of informing economic profiles of marketed medicines. Following the first section of this programs, we presented the principles of designing a study, measuring costs and outcomes, and performing sensitivity analyses. Generally, four designs of economic evaluations are available to perform economic evaluations, each of which has specific strengths and weaknesses. Valuation of outcomes and costs may differ in methods, mainly based on the requirements and applicability of study. The possible factors leading to variation of results should be analyzed using analytic methods with different techniques.
出处 《中国循证医学杂志》 CSCD 2006年第3期218-223,共6页 Chinese Journal of Evidence-based Medicine
关键词 经济学评价 上市后药物 方法 Economic evaluation Marketed medicines Methods
  • 相关文献

参考文献1

二级参考文献23

  • 1Fox AW.Phase II and phase III clinical studies.In:Fletcher AJ,Edwards L,Fox AW,Stonier P eds.Principles and practices of pharmaceutical medicine.John Wiley & Sons,Ltd.2002
  • 2Edwards R,Olsson S.WHO Programme - Global Monitoring.In:Mann RD,Andrews EB.Pharmacovigilance.John Wiley & Sons,Ltd.2002.
  • 3Johnson-Pratt LR.Phase IV drug development:post-marketing studies.In:Fletcher AJ,Edwards L,Fox AW,Stonier P eds.Principles and practices of pharmaceutical medicine.John Wiley & Sons,Ltd.2002.
  • 4Che MF,Han BS.The preparation and implementation of essential medicines list in China.Chinese Pharmaceutical Issues.2000;14(1):19-21.
  • 5Xu FK.The selection of essential medicines in China.Chinese Hospital Management.1997;17(4):23-24.
  • 6Li SL,Cao LY,Xiao AL,Yan L,Lan F.Evidence-based evaluation of essential medicines.Chinese Pharmaceutical Issues.2003;17(6):337-339.
  • 7Data from OECD Health Database.Available from http://www.euro.who.int/document/e73096.pdf.
  • 8Data from the Chinese Ministry of Health.Available from:http://61.49.18.68/statistics/digest03/t33.htm.
  • 9Sun X,Li YP,Cao LY,Wiffen P.A perspective of evidence-based medicine on post-marketing drug evaluation in China:present,problems and strategies.The 8th Global Health Forum.Mexico City,Mexico.2004.
  • 10Canadian Coordinating Office for Health Technology Assessment.Guidelines for economic evaluation of pharmaceuticals:Canada.2nd Edition.November 1997.

共引文献2

同被引文献4

引证文献3

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部